dapagliflozin + metformin + placebo

dapagliflozin + metformin + placebo refers to a specific treatment arm in the Phase 3 TRIAD clinical trial (NCT04841395) sponsored by Eurofarma Laboratorios S.A. for the treatment of type 2 diabetes mellitus. This regimen consists of the active agents dapagliflozin (a sodium-glucose cotransporter 2 inhibitor) and metformin (a biguanide), administered alongside a placebo for sitagliptin to maintain the double-blind study design. Dapagliflozin works by blocking glucose reabsorption in the proximal tubule of the kidney, leading to increased urinary glucose excretion, while metformin primarily acts by decreasing hepatic gluconeogenesis and increasing peripheral insulin sensitivity. This combination is evaluated as a dual-therapy comparator against a triple fixed-dose combination (N0892) in patients whose glycemic levels are inadequately controlled on metformin monotherapy.

Brand names

Glifage XR

Other names

Forxiga + Glifage XR + Placebo